Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.
Saved in:
| Title: | Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. |
|---|---|
| Authors: | Sayed CJ; Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany. Electronic address: christopher_sayed@med.unc.edu., Kirby B; European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; St Vincent's University Hospital, Elm Park and the Charles Institute, University College Dublin, Dublin, Republic of Ireland., Garg A; Department of Dermatology, Northwell, New Hyde Park, New York., Naik HB; Department of Dermatology, University of California, San Francisco, California., Kimball AB; Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts., Zouboulis CC; European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany., Jemec GBE; European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; Department of Dermatology, Herlev-Gentofte Hospital, University Hospital, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Kokolakis G; Psoriasis Research and Treatment Center, Clinic of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ingram JR; European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, UK., Morita A; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Deherder D; UCB, Braine-l'Alleud, Belgium., Crater C; UCB, Morrisville, North Carolina., Rolleri RL; UCB, Morrisville, North Carolina., Vaux T; UCB, Slough, UK., Lambert J; UCB, Colombes, France., Lukowski B; Vedim/UCB, Warsaw, Poland., Bechara FG; Department of Dermatology, Venereology, and Allergology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; Department of Dermatology, ICH - International Center for Hidradenitis Suppurativa/Acne Inversa, Ruhr-University Bochum, Bochum, Germany. |
| Source: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2026 Mar; Vol. 94 (3), pp. 867-878. Date of Electronic Publication: 2025 Nov 15. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
